November 21, 2014Open Access
View Full PaperA putative placebo analysis of the effects of LCZ696 on clinical outcomes in heart failure
Structured PICO
Does sacubitril/valsartan (LCZ696) reduce mortality and heart failure hospitalization in heart failure patients compared to a putative placebo?
P
Population
Patients with heart failure on comprehensive background beta-blocker and mineralocorticoid receptor antagonist therapy
I
Intervention
Sacubitril/valsartan (LCZ696) added to comprehensive background beta-blocker and mineralocorticoid receptor antagonist therapy
C
Comparator
Putative placebo
O
Outcome
Cardiovascular mortality, all-cause mortality, and heart failure hospitalizationhard clinical
Indirect comparisons suggest that sacubitril/valsartan (LCZ696) significantly reduces mortality and heart failure hospitalizations compared to a putative placebo, even when added to background beta-blocker and MRA therapy.
Abstract
These indirect comparisons of LCZ696 with a putative placebo show that the strategy of combined angiotensin receptor blockade and neprilysin inhibition led to striking reductions in cardiovascular and all-cause mortality, as well as heart failure hospitalization. These benefits were obtained even though LCZ696 was added to comprehensive background beta-blocker and mineralocorticoid receptor antagonist therapy.